title: Zotepine in the treatment of acute hospitalized schizophrenic episodes.
abstract: The atypical antipsychotic zotepine was studied in an open, multicentre uncontrolled, post-marketing surveillance study in 108 schizophrenic patients hospitalized in 12 trial centres in Austria. Within the dosage range of 50-450 mg (mean at the end of the study, 207 +/- 125 mg/day), a significant reduction of positive as well as negative symptoms was noted. There was no increase in extrapyramidal side-effects during the study and a significant decrease in akathisia scores. The medication was well tolerated during the 42-day observation period. Zotepine improved both positive and negative symptoms and was not accompanied by extrapyramidal side-effects, justifying its classification as an atypical antipsychotic.
authors.affiliation: Klinische Abteilung für Allgemeine Psychiatrie, Universitätsklinik für Psychiatrie, Wien, Austria. sk@akh-wien.ac.at
authors.forename: S
authors.initials: S
authors.lastname: Kasper
authors.forename: S
authors.initials: S
authors.lastname: Quiner
authors.forename: C
authors.initials: C
authors.lastname: Barnas
authors.forename: H
authors.initials: H
authors.lastname: Fabisch
authors.forename: M
authors.initials: M
authors.lastname: Haushofer
authors.forename: C
authors.initials: C
authors.lastname: Sackel
authors.forename: P
authors.initials: P
authors.lastname: König
authors.forename: A
authors.initials: A
authors.lastname: Lingg
authors.forename: T
authors.initials: T
authors.lastname: Platz
authors.forename: H
authors.initials: H
authors.lastname: Rittmannsberger
authors.forename: C
authors.initials: C
authors.lastname: Stuppäck
authors.forename: M
authors.initials: M
authors.lastname: Willeit
authors.forename: H G
authors.initials: HG
authors.lastname: Zapotoczky
mesh_terms: D000208:Acute Disease; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001317:Austria; D003988:Dibenzothiepins / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010343:Patient Admission; D011358:Product Surveillance, Postmarketing; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D003988:Dibenzothiepins; C022172:zotepine